comparemela.com
Home
Live Updates
Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya (fingolimod) dosing regimen patent : comparemela.com
Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya (fingolimod) dosing regimen patent
Basel, June 21, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a new, negative decision regarding the validity of US Patent No.
Related Keywords
Delaware ,
United States ,
America ,
Isabella Zinck ,
Amy Wolf ,
Nicole Zinsli Somm ,
Samir Shah ,
Julie Masow ,
Parag Mahanti ,
Sloan Simpson ,
Meghan Odonnell ,
Alina Levchuk ,
Novartis Division Communications ,
Twitter ,
Us Court ,
Novartis Us External Communications ,
Novartis External Communications ,
Us District Court ,
Novartis ,
Exchange Commission ,
Federal Circuit ,
Abbreviated New Drug Application ,
Forward Looking Statement ,
Information Technology ,
Life Sciences ,
Pharmaceuticals ,
Pharmaceuticals Policy ,
Articles ,
Fingolimod ,
Generic Drug ,
Industry Economics ,
Research And Development ,
comparemela.com © 2020. All Rights Reserved.